Regeneron Pharmaceuticals Inc. (REGN)

300.19
NASDAQ : Health Technology
Prev Close 301.57
Day Low/High 298.70 / 303.51
52 Wk Low/High 271.37 / 442.00
Avg Volume 707.40K
Exchange NASDAQ
Shares Outstanding 107.98M
Market Cap 33.14B
EPS 22.60
P/E Ratio 16.74
Div & Yield N.A. (N.A)

Latest News

Real Money Post-Industrial Average Continues to Outpace Major Indices

Real Money Post-Industrial Average Continues to Outpace Major Indices

RMPIA is up 20.9% in the first nine months of 2019.

Pfizer Edges Higher After Positive Trials for Moderate-to-Severe Eczema Drug

Pfizer Edges Higher After Positive Trials for Moderate-to-Severe Eczema Drug

Pfizer shares edged higher Friday after the company posted promising results from trials of a drug it's developing to treat patients with moderate-to-severe eczema.

Regeneron Rises After European Committee Adopts Positive Opinion on Dupixent

Regeneron Rises After European Committee Adopts Positive Opinion on Dupixent

The company's treatment for nasal polyps receives positive feedback from the European Medicines Agency's Committee for Medicinal Products for Human Use.

Otezla Price Under Microscope -- but Look Closely and It Checks Out

Otezla Price Under Microscope -- but Look Closely and It Checks Out

Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.

Regeneron Announces Upcoming Investor Conference Presentation

Regeneron Announces Upcoming Investor Conference Presentation

TARRYTOWN, N.Y.

FDA Approves EYLEA® (aflibercept) Injection Prefilled Syringe

FDA Approves EYLEA® (aflibercept) Injection Prefilled Syringe

TARRYTOWN, N.Y.

Real Money Post-Industrial Average Leads Major Indexes So Far for Year

Real Money Post-Industrial Average Leads Major Indexes So Far for Year

In July, the RMPIA climbed 0.6%, bringing its year-to-date return to just over 21%.

Will Gilead Sciences Stock Really Rally 33% From Here?

Will Gilead Sciences Stock Really Rally 33% From Here?

Shares of Gilead Sciences are jumping higher on its increased investment in Galapagos and a new outperform rating from Wells Fargo.

Real Money Post Industrial Average Enjoyed a Stellar First Half of 2019

Real Money Post Industrial Average Enjoyed a Stellar First Half of 2019

There are a number of RMPIA companies that will be beneficiaries of Back to School and holiday spending.

FDA Approves Dupixent® (dupilumab) For Chronic Rhinosinusitis With Nasal Polyposis

FDA Approves Dupixent® (dupilumab) For Chronic Rhinosinusitis With Nasal Polyposis

* First biologic medicine for adults with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP)

2 Well-Known Stocks You Should Consider Shorting This Week

2 Well-Known Stocks You Should Consider Shorting This Week

These bearish bets are showing both technical and quantitative deterioration.

TheStreet Quant Rating: C+ (Hold)